DPP4 and metabolic dysfunction-associated steatotic liver disease: Given HuR’s complex role in insulin sensitivity, a therapeutic strategy combining HuR modulation with insulin sensitizers—such as thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, biguanides (e.g., metformin), and dipeptidyl peptidase IV (DPP-4) inhibitors—may provide more effective treatment for NAFLD [40].